Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites.

Leber MF, Baertsch MA, Anker SC, Henkel L, Singh HM, Bossow S, Engeland CE, Barkley R, Hoyler B, Albert J, Springfeld C, Jäger D, von Kalle C, Ungerechts G.

Mol Ther Oncolytics. 2018 Apr 12;9:30-40. doi: 10.1016/j.omto.2018.04.002. eCollection 2018 Jun 29.

2.

Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.

Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS.

EBioMedicine. 2018 May;31:17-24. doi: 10.1016/j.ebiom.2018.04.020. Epub 2018 Apr 23. Review.

3.

Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.

Speck T, Heidbuechel JPW, Veinalde R, Jaeger D, von Kalle C, Ball CR, Ungerechts G, Engeland CE.

Clin Cancer Res. 2018 May 1;24(9):2128-2137. doi: 10.1158/1078-0432.CCR-17-2651. Epub 2018 Feb 6.

PMID:
29437789
4.

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy.

Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaao1641. doi: 10.1126/scitranslmed.aao1641.

PMID:
29298865
5.

Virotherapy Research in Germany: From Engineering to Translation.

Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM.

Hum Gene Ther. 2017 Oct;28(10):800-819. doi: 10.1089/hum.2017.138. Review.

PMID:
28870120
6.

A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.

Hajda J, Lehmann M, Krebs O, Kieser M, Geletneky K, Jäger D, Dahm M, Huber B, Schöning T, Sedlaczek O, Stenzinger A, Halama N, Daniel V, Leuchs B, Angelova A, Rommelaere J, Engeland CE, Springfeld C, Ungerechts G.

BMC Cancer. 2017 Aug 29;17(1):576. doi: 10.1186/s12885-017-3604-y.

7.

A Tupaia paramyxovirus vector system for targeting and transgene expression.

Engeland CE, Bossow S, Hudacek AW, Hoyler B, Förster J, Veinalde R, Jäger D, Cattaneo R, Ungerechts G, Springfeld C.

J Gen Virol. 2017 Sep;98(9):2248-2257. doi: 10.1099/jgv.0.000887. Epub 2017 Sep 8.

PMID:
28809150
8.

Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.

Veinalde R, Grossardt C, Hartmann L, Bourgeois-Daigneault MC, Bell JC, Jäger D, von Kalle C, Ungerechts G, Engeland CE.

Oncoimmunology. 2017 Jan 31;6(4):e1285992. doi: 10.1080/2162402X.2017.1285992. eCollection 2017.

9.

Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses.

Ungerechts G, Bossow S, Leuchs B, Holm PS, Rommelaere J, Coffey M, Coffin R, Bell J, Nettelbeck DM.

Mol Ther Methods Clin Dev. 2016 Apr 6;3:16018. doi: 10.1038/mtm.2016.18. eCollection 2016. Review.

10.

Gene and cell therapy for pancreatic cancer.

Singh HM, Ungerechts G, Tsimberidou AM.

Expert Opin Biol Ther. 2015 Apr;15(4):505-16. doi: 10.1517/14712598.2015.1001734. Epub 2015 Jan 13. Review.

PMID:
25582170
11.

CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.

Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W, Jäger D, von Kalle C, Ungerechts G.

Mol Ther. 2014 Nov;22(11):1949-59. doi: 10.1038/mt.2014.160. Epub 2014 Aug 26.

12.

MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus.

Baertsch MA, Leber MF, Bossow S, Singh M, Engeland CE, Albert J, Grossardt C, Jäger D, von Kalle C, Ungerechts G.

Cancer Gene Ther. 2014 Sep;21(9):373-80. doi: 10.1038/cgt.2014.40. Epub 2014 Aug 22.

PMID:
25145311
13.

Artificial riboswitches for gene expression and replication control of DNA and RNA viruses.

Ketzer P, Kaufmann JK, Engelhardt S, Bossow S, von Kalle C, Hartig JS, Ungerechts G, Nettelbeck DM.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):E554-62. doi: 10.1073/pnas.1318563111. Epub 2014 Jan 21.

14.

Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.

Grossardt C, Engeland CE, Bossow S, Halama N, Zaoui K, Leber MF, Springfeld C, Jaeger D, von Kalle C, Ungerechts G.

Hum Gene Ther. 2013 Jul;24(7):644-54. doi: 10.1089/hum.2012.205.

15.

Chemovirotherapy of malignant melanoma with a targeted and armed oncolytic measles virus.

Kaufmann JK, Bossow S, Grossardt C, Sawall S, Kupsch J, Erbs P, Hassel JC, von Kalle C, Enk AH, Nettelbeck DM, Ungerechts G.

J Invest Dermatol. 2013 Apr;133(4):1034-42. doi: 10.1038/jid.2012.459. Epub 2012 Dec 6.

16.

Targeted lentiviral vectors pseudotyped with the Tupaia paramyxovirus glycoproteins.

Enkirch T, Kneissl S, Hoyler B, Ungerechts G, Stremmel W, Buchholz CJ, Springfeld C.

Gene Ther. 2013 Jan;20(1):16-23. doi: 10.1038/gt.2011.209. Epub 2012 Jan 5.

PMID:
22218301
17.

Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.

Zaoui K, Bossow S, Grossardt C, Leber MF, Springfeld C, Plinkert PK, Kalle Cv, Ungerechts G.

Cancer Gene Ther. 2012 Mar;19(3):181-91. doi: 10.1038/cgt.2011.75. Epub 2011 Nov 11.

PMID:
22076043
18.

Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.

Bossow S, Grossardt C, Temme A, Leber MF, Sawall S, Rieber EP, Cattaneo R, von Kalle C, Ungerechts G.

Cancer Gene Ther. 2011 Aug;18(8):598-608. doi: 10.1038/cgt.2011.30. Epub 2011 Jun 24.

19.

Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.

Miest TS, Yaiw KC, Frenzke M, Lampe J, Hudacek AW, Springfeld C, von Messling V, Ungerechts G, Cattaneo R.

Mol Ther. 2011 Oct;19(10):1813-20. doi: 10.1038/mt.2011.92. Epub 2011 May 24.

20.

MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.

Leber MF, Bossow S, Leonard VH, Zaoui K, Grossardt C, Frenzke M, Miest T, Sawall S, Cattaneo R, von Kalle C, Ungerechts G.

Mol Ther. 2011 Jun;19(6):1097-106. doi: 10.1038/mt.2011.55. Epub 2011 Apr 5.

21.

Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.

Ungerechts G, Frenzke ME, Yaiw KC, Miest T, Johnston PB, Cattaneo R.

Gene Ther. 2010 Dec;17(12):1506-16. doi: 10.1038/gt.2010.103. Epub 2010 Aug 5.

22.

Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine.

Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Johnston PB, Parker WB, Sorscher EJ, Cattaneo R.

Cancer Res. 2007 Nov 15;67(22):10939-47.

23.

An immunocompetent murine model for oncolysis with an armed and targeted measles virus.

Ungerechts G, Springfeld C, Frenzke ME, Lampe J, Parker WB, Sorscher EJ, Cattaneo R.

Mol Ther. 2007 Nov;15(11):1991-7. Epub 2007 Aug 21.

24.

Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.

Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R.

Cancer Res. 2006 Aug 1;66(15):7694-700.

25.

Severe impairment of dendritic cell allostimulatory activity by Sendai virus vectors is overcome by matrix protein gene deletion.

Armeanu S, Bitzer M, Smirnow I, Bossow S, Appel S, Ungerechts G, Bernloehr C, Neubert WJ, Lauer UM, Brossart P.

J Immunol. 2005 Oct 15;175(8):4971-80.

26.

Recombinant Sendai virus for efficient gene transfer to human airway epithelium.

Pinkenburg O, Vogelmeier C, Bossow S, Neubert WJ, Lutz RB, Ungerechts G, Lauer UM, Bitzer M, Bals R.

Exp Lung Res. 2004 Mar;30(2):83-96.

PMID:
14972769
27.

Efficient propagation of single gene deleted recombinant Sendai virus vectors.

Bernloehr C, Bossow S, Ungerechts G, Armeanu S, Neubert WJ, Lauer UM, Bitzer M.

Virus Res. 2004 Feb;99(2):193-7. Erratum in: Virus Res. 2004 May;101(2):205.

PMID:
14749185
28.

Reduced toxicity of F-deficient Sendai virus vector in the mouse fetus.

Waddington SN, Buckley SM, Bernloehr C, Bossow S, Ungerechts G, Cook T, Gregory L, Rahim A, Themis M, Neubert WJ, Coutelle C, Lauer UM, Bitzer M.

Gene Ther. 2004 Apr;11(7):599-608.

PMID:
14724676
29.

Cell cycle independent infection and gene transfer by recombinant Sendai viruses.

Armeanu S, Ungerechts G, Bernloehr C, Bossow S, Gregor M, Neubert WJ, Lauer UM, Bitzer M.

J Virol Methods. 2003 Mar;108(2):229-33.

PMID:
12609691
30.

Negative-strand RNA viral vectors: intravenous application of Sendai virus vectors for the systemic delivery of therapeutic genes.

Bitzer M, Ungerechts G, Bossow S, Graepler F, Sedlmeier R, Armeanu S, Bernloehr C, Spiegel M, Gross CD, Gregor M, Neubert WJ, Lauer UM.

Mol Ther. 2003 Feb;7(2):210-7.

31.

Characterization of Drosophila hemoglobin. Evidence for hemoglobin-mediated respiration in insects.

Hankeln T, Jaenicke V, Kiger L, Dewilde S, Ungerechts G, Schmidt M, Urban J, Marden MC, Moens L, Burmester T.

J Biol Chem. 2002 Aug 9;277(32):29012-7. Epub 2002 Jun 4.

32.

Caspase-8 and Apaf-1-independent caspase-9 activation in Sendai virus-infected cells.

Bitzer M, Armeanu S, Prinz F, Ungerechts G, Wybranietz W, Spiegel M, Bernlöhr C, Cecconi F, Gregor M, Neubert WJ, Schulze-Osthoff K, Lauer UM.

J Biol Chem. 2002 Aug 16;277(33):29817-24. Epub 2002 May 20.

Supplemental Content

Loading ...
Support Center